Safi R. Bahcall, President and CEO at SYNTA PHARMACEUTICALS CORP (SNTA), bought 20,000 shares at $2.80 ($57K) on 2009-08-06, disclosed to the SEC on 2009-08-07.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.78 | 200 | $556 | 1.0% |
| 2 | $2.80 | 6,079 | $17K | 29.9% |
| 3 | $2.82 | 300 | $846 | 1.5% |
| 4 | $2.83 | 1,980 | $6K | 9.8% |
| 5 | $2.85 | 2,000 | $6K | 10.0% |
| 6 | $2.88 | 196 |
| $564 |
| 1.0% |
| 7 | $2.89 | 9,245 | $27K | 46.9% |
| Total | $2.85 avg | 20,000 | $57K | 100% |
| Filing → |
| SNTA | BUY | 2013-06-24 | $82K | — | Filing → |
| SNTA | BUY | 2013-06-17 | $41K | — | Filing → |
| SNTA | BUY | 2013-06-06 | $40K | — | Filing → |